INVEST
min $250
Acute Myeloid Leukemia (AML), cancer of the white blood cells; destroys the immune system
Problem:
Problems with current treatments:
Solution:
Hodgkin’s Lymphoma, cancer that starts in the lymphatic system and impacts the immune system.
The problems with current treatments:
Acute Respiratory Distress Syndrome (ARDS), an inflammatory lung condition brought on by Pneumonia, COVID-19 and other reasons.
Solution: Our drug would be 'first-in-class,' meaning we will be curing ARDS in a new way. Our goal is to become the first targeted treatment and a patient’s main option.
Parkinson's disease is a life-threatening neurological brain disorder.
Solution: Our drug would be a 'first-in-class’ drug for treating Parkinson’s disease. We would offer a safe, targeted treatment that allows patients to overcome long term suffering and life-threatening results.
Cancer, lung disease, and brain disorders seem so different. How can one drug treat many different issues?
These companies were chosen because of their similar pipeline profiles to PhorMed.
Qualifications:
With projected market values somewhere between $290M-1.2B, this gives PhorMed remarkable growth potential at $53 Million. Invest now and grow with the company.
Anti-inflammation
Newest discovered: RP-323 is a breakthrough treatment for inflammation
Kills cancer cells, repairs damaged & mutated cells
Our drug repairs and restores damaged and mutated cells, can kill a cancer cell, and boosts cancer fighting immune response. Supported by clinical evidence.
Fast-Track designation
We are on the Fast Track. Literally. The FDA has granted us their “Fast Track” status, which speeds up approval process and greatly reduces overall cost.
Investment opportunity
As an investor you will have the opportunity to buy low compared to other similar companies and grow with the company.